ERBB2 and endometrial cancer: A phase II basket trial (NCT06003231) is focusing on patients with previously treated advanced solid tumors that express HER2 (≥1 IHC), including patients with ovarian and endometrial cancer, in order to evaluate the efficacy of RC48 as a new treatment option in this subgroup of patients with limited available therapies [131].